Infection Prevention Strategies for Novel Coronavirus in Pregnant and Puerperal Women

More than two years have passed since the reported emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 SARS CoV 2 .In the last two years, various clinical studies have been carried out, and the mechanism for the onset of coronavirus infection disease 2019 COVID 19 is being elucidated. According to previous clinical studies, pregnancies at an older age, obesity, hypertension, diabetes, etc. are considered to be risk factors for the aggravation of COVID 19.Therefore, pregnant women with such a background should be careful about SARS CoV 2 infection. In particular, when a pregnant woman is infected with SARS CoV 2 in the latter half of pregnancy, it is considered that the infected pregnant woman is likely to become severely affected by COVID 19.There is no medical evidence that the COVID 19 mRNA vaccine BNT162b2, mRNA 1273 has adverse effects on pregnancy, fetal, breast milk and genital organs. Therefore, the World Health Organization WHO recommends that women who are pregnant, breastfeeding, or planning to become pregnant should be vaccinated with the COVID 19 vaccine. Oral medication prescribed for mild cases of COVID 19 Molnupiravir is not approved for pregnant women. In addition, cocktail antibody medications for pregnant women are also conditional prescriptions. In this mini review, we would like to discuss the treatment method of COVID 19 in pregnant women with the latest findings. Takuma Hayashi | Ikuo Konishi "Infection Prevention Strategies for Novel Coronavirus in Pregnant and Puerperal Women" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-2 , February 2022, URL: https://www.ijtsrd.com/papers/ijtsrd49275.pdf Paper URL: https://www.ijtsrd.com/medicine/other/49275/infection-prevention-strategies-for-novel-coronavirus-in-pregnant-and-puerperal-women/takuma-hayashi